Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
Authors
Márcio Sommer Bittencourt (ORCID: https://orcid.org/0000-0002-3711-1754)
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
5.55
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
Márcio Sommer Bittencourt, Lídia Zytynski Moura, Sanderson Cauduro, Luka David Lechinewski et al.
Citations
4 citations
Journal
Circulation
Topics
Chemotherapy-induced cardiotoxicity and mitigation
Field-Weighted Citation Impact (FWCI)
5.55
article
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
Márcio Sommer Bittencourt, Lídia Zytynski Moura, Sanderson Cauduro, Luka David Lechinewski, Mônica Samuel Ávila, Marcely Gimenes Bonatto, Edimar Alcides Bocchi, Nadège Costa, Andressa de Oliveira Coiradas, Takahiro Ota, Silvia Moreira Ayub‐Ferreira, Talita Beithum Ribeiro Mialski, Rafael Torres, A. Santos Da Costa, Julyana Maiolino, Laís Contin, Larissa Arlete Mosko
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
CirculationVol. 152(25)
Institutions
University of Pittsburgh (US), Pontifícia Universidade Católica do Paraná (BR), Santa Casa Hospital (BR), Hospital Erasto Gaertner (BR), Hospital IPO (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
OpenAlex Percentile
Openalex Percentile: Top 3%
Topics
Chemotherapy-induced cardiotoxicity and mitigation